Scholtz & Company’s Sonnet BioTherapeutics SONN Stock Holding History

Scholtz & Company’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4	Closed	-$23K	–	76
2021 Q1	$23K	Buy	+4	New	+$25.3K	0.01%	68

Other funds holding SONN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MSFS

Main Street Financial Solutions Newtown, Pennsylvania $1.34B AUM 19.49% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Scholtz & Company's SONN Position: Q2 2021 in Review

Scholtz & Company sold out of Sonnet BioTherapeutics (SONN) in Q2 2021, closing a stake of 4 shares — an estimated $23K sold.

Scholtz & Company first reported a position in SONN in Q1 2021 and held it in 1 quarter. The position peaked at $23K in Q1 2021. 9 funds tracked by Wall St. Rank hold SONN as of Q2 2021.

Scholtz & Company reported no remaining Sonnet BioTherapeutics position as of Q2 2021 after selling out during the quarter.
Scholtz & Company sold 4 Sonnet BioTherapeutics shares in Q2 2021, an estimated $23K.
Scholtz & Company first reported a position in Sonnet BioTherapeutics in Q1 2021 and held it in 1 quarter.
Scholtz & Company's Sonnet BioTherapeutics position peaked at $23K in Q1 2021.
9 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q2 2021.

Based on Scholtz & Company's 13F filing for Q2 2021, filed 9 Aug 2021.